Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

MHLWRegulator guidanceBioequivalenceMedicinesHigh confidenceLast verified October 5, 2026

JP BE guideline, formulation changes (oral solid)

Guideline for Bioequivalence Studies for Formulation Changes of Oral Solid Dosage Forms

Current edition

March 19, 2020 (English translation)

About this standard

Sets the tests that show a product stays bioequivalent after the non-active components or composition of an oral solid product change after approval. The tests depend on the level of the change.

Recognition by market

Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts

No market listing is published yet.

Testing requirements that cite it

Open the market page and its pathway pages for the full requirement, protocol and report content

Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.

Not legal or regulatory advice. Check the current official rules before you act. Parts of the approvals data are official open data reused under open licences. Data sources.

LinkedInLinkedInXXYouTubeYouTube